bluebird bio
$90.509876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.
$90.50
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
+$5.70 (+6.78%) Today
+$0.75 (+0.84%) As of 8:00 PM EST after-hours
Why Robinhood?
You can buy or sell bluebird bio and other stocks, options, ETFs, and crypto commission-free!
About BLUE
bluebird bio, Inc. Common Stock, also called bluebird bio, is a clinical-stage biotechnology company, which engages in the development of potential gene therapies for severe genetic diseases and cancer. Read More Its integrated product platform includes gene therapy, cancer immunotherapy, and gene editing. Its product pipeline includes Lenti-D, LentiGlobin, BCL11a shRNA, bb2121, and bb21217. The company was founded by Philippe Leboulch and Ronald C. Dorazio on April 16, 1992 and is headquartered in Cambridge, MA.
CEO
Employees
764
Headquarters
Cambridge, Massachusetts
Founded
1992
Market Cap
4.65B
Price-Earnings Ratio
0.00
Dividend Yield
0.00
Average Volume
2.00M
High Today
$90.74
Low Today
$85.14
Open Price
$86.75
Volume
2.33M
52 Week High
$163.43
52 Week Low
$71.42
Collections
Analyst Ratings
67%
of 21 ratings
Buy
67%
Hold
33%
Sell
0%
BLUE Earnings
-$3.73
-$3.18
-$2.62
-$2.07
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Q3 2019
Q4 2019
Estimated
—
Actual
Expected Feb 20, After Hours